Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies

Authors


John F. Johanson MSc, MD, Rockford Gastroenterology Associates, 401 Roxbury Road, Rockford, IL 61107, USA.
Tel: 815-397-7340; fax: 815-397-2156;
e-mail: johnfj@uic.edu

Abstract

Abstract  This article reviews the efficacy and tolerability of traditional therapies for irritable bowel syndrome (IBS) and concludes that they are limited by both poor efficacy and adverse effects. Serotonin, a neurotransmitter found mainly in the gut, appears to represent a link in IBS pathophysiological processes – altered gut motility, abnormal intestinal secretion and visceral hypersensitivity. Recently, available treatments for IBS have targeted serotonin receptors that are involved in motor, sensory and secretory functions of the gut. Serotonergic agents, such as alosetron (a 5-HT3 receptor antagonist) and tegaserod (a selective 5-HT4 receptor partial agonist), provide global relief of the multiple symptoms of IBS with diarrhoea and IBS with constipation, respectively, and represent important additions to the IBS treatment armamentarium.

Ancillary